Is Health.Global overvalued or undervalued?

As of 17 November 2025, Health.Global's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently considered overvalued, particularly highlighted by its PE ratio of 293.88, a price-to-book value of 47.10, and an EV to EBITDA of 28.12. Compared to its peers, Apollo Hospitals, which is rated attractive, has a significantly lower PE ratio of 64.41, while Max Healthcare, categorized as very expensive, has a PE ratio of 77.22.
The high valuation ratios for Health.Global suggest that the market has priced in excessive growth expectations, which may not be sustainable. Despite its strong historical performance, with a year-to-date return of 50.96% compared to the Sensex's 8.72%, the current valuation metrics indicate that the stock may not offer a favorable risk-reward profile at this time.